Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15655. [Epub ahead of print] No abstract available.

PMID:
30407614
2.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

3.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

4.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
5.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
6.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3.

PMID:
28162984
7.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. No abstract available.

8.

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R.

Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17.

9.

Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.

Balleari E, Salvetti C, Del Corso L, Filiberti R, Bacigalupo A, Bellodi A, Beltrami G, Bergamaschi M, Berisso G, Calzamiglia T, Carella AM, Cavalleri M, Da Col A, Favorini S, Forni GL, Goretti R, Miglino M, Mitscheuning L, Molinari E, Racchi O, Scudeletti M, Tassara R, Gobbi M, Lemoli R, Clavio M.

Leuk Res. 2015 Aug;39(8):846-52. doi: 10.1016/j.leukres.2015.05.007. Epub 2015 Jun 22.

PMID:
26145790
10.

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, Ottaggio L, Mingari MC, Zupo S, Cutrona G, Pierri I, Balleari E, Pattarozzi A, Calvaruso M, Tripodo C, Ferrarini M, de Totero D.

Haematologica. 2014 Jun;99(6):1078-87. doi: 10.3324/haematol.2013.091405. Epub 2014 Feb 21.

11.

Cardiovascular adverse events complicating the administration of rituximab: report of two cases.

Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, Molinari E, Ponassi I, Oneto C, Sicbaldi V, Ghio R.

Tumori. 2013 Nov-Dec;99(6):288e-92e. doi: 10.1700/1390.15471.

PMID:
24503806
12.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S.

Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. No abstract available.

13.

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.

Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D'Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA.

Leuk Lymphoma. 2013 Nov;54(11):2458-65. doi: 10.3109/10428194.2013.778406. Epub 2013 Mar 27.

PMID:
23432724
14.

High-dose recombinant human erythropoietin for "low-risk" myelodysplastic patients: is more better?

Balleari E, Corso LD.

Chin Clin Oncol. 2012 Dec;1(2):25. doi: 10.3978/j.issn.2304-3865.2012.12.06. No abstract available.

15.

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, Balleari E, Racchi O, Zoppoli G, Orsi A, Alicino C, Icardi G, Marincola FM, Zupo S, Ferrarini M, De Maria A.

Blood. 2012 Aug 30;120(9):1954-7. No abstract available.

16.

Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.

Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R.

Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26.

PMID:
21794914
17.

A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.

Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso A, Di Renzo N, Balleari E, Neri S, Quarta G, Ferrara R, Vigliotti ML, Polimeno G, Musto P, Consoli U, Zoboli A, Buda G, Pastorini A, Masini L.

Leuk Lymphoma. 2011 Oct;52(10):1942-8. doi: 10.3109/10428194.2011.584006. Epub 2011 Jun 12.

PMID:
21663513
18.

Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Zoppoli G, Bianchi F, Bruzzone A, Calvia A, Oneto C, Passalia C, Balleari E, Bedognetti D, Ponomareva E, Nazzari E, Castelletti L, Castellan L, Minuto F, Ghio R, Ferone D.

Pituitary. 2012 Jun;15(2):209-14. doi: 10.1007/s11102-011-0311-6. Review.

PMID:
21503687
19.

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A.

J Immunol. 2011 May 15;186(10):6044-55. doi: 10.4049/jimmunol.1004095. Epub 2011 Apr 15.

20.

An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease.

Giannoni P, Scaglione S, Quarto R, Narcisi R, Parodi M, Balleari E, Barbieri F, Pattarozzi A, Florio T, Ferrini S, Corte G, de Totero D.

Haematologica. 2011 Jul;96(7):1015-23. doi: 10.3324/haematol.2010.029736. Epub 2011 Apr 12.

21.

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, Balleari E, Musto P, Neri S, Aloe Spiriti MA, Cox MC.

Ann Oncol. 2010 Jul;21(7):1486-91. doi: 10.1093/annonc/mdp531. Epub 2009 Nov 17.

PMID:
19920060
22.

Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?

Balleari E, Bruzzone A.

Leuk Res. 2009 Sep;33(9):1164-5. doi: 10.1016/j.leukres.2009.04.020. Epub 2009 May 14. No abstract available.

PMID:
19446332
23.

Purpura as the initial presentation for small-cell lung cancer.

Zoppoli G, Balleari E, Bruzzone A, Mastracci L, Ghio R.

Onkologie. 2009 May;32(5):277-9. doi: 10.1159/000209318. Epub 2009 Apr 20.

PMID:
19420975
24.

Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.

Clavio M, Ghiso A, Ghiggi C, Spriano M, Colombo N, Grasso R, Varaldo R, Miglino M, Pierri I, Olcese F, Aquino S, Biasco S, Balleari E, Carella AM, Sessarego M, Gobbi M.

Oncol Rep. 2009 Apr;21(4):1045-52.

PMID:
19288007
25.

The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.

Olcese F, Clavio M, Rossi E, Spriano M, Ballerini F, Canepa L, Pierri I, Aquino S, Varaldo R, Manna A, Secondo V, Racchi O, Balleari E, Orcioni GF, Carella AM, Ghio R, Gobbi M.

Ann Hematol. 2009 Sep;88(9):855-61. doi: 10.1007/s00277-009-0699-5. Epub 2009 Feb 3.

PMID:
19189105
26.

From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients.

Zoppoli G, Bruzzone B, Caligiuri P, Picciotto A, Balleari E, Bruzzone A, Icardi G, Ghio R.

Br J Haematol. 2009 Mar;144(6):969-70. doi: 10.1111/j.1365-2141.2008.07539.x. Epub 2008 Dec 12. No abstract available. Erratum in: Br J Haematol. 2009 Nov;147(3):411. Gabriele, Zoppoli [corrected to Zoppoli, Gabriele]; Bianca, Bruzzone [corrected to Bruzzone, Bianca]; Patrizia, Caligiuri [corrected to Caligiuri, Patrizia]; Antonino, Picciotto [corrected to Picciotto, Antonino]; Enrico, Balleari [corrected to Balleari, E.

PMID:
19120363
27.

CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Abate Osella S, Bernengo MG, Bianchi Scarrà G.

Pigment Cell Melanoma Res. 2008 Dec;21(6):700-9. doi: 10.1111/j.1755-148X.2008.00512.x. Epub 2008 Oct 22.

PMID:
18983535
28.

Does 18F-fluorodeoxyglucose PET/CT have a role in the management of pulmonary and extra pulmonary sarcoidosis?

Carbone R, Douroukas A, Arena V, Cantalupi D, Balleari E, Ghio R, Pelosi E.

Monaldi Arch Chest Dis. 2008 Jun;69(2):81-2. No abstract available.

PMID:
18837423
29.

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network.

Cancer. 2008 Oct 1;113(7):1588-95. doi: 10.1002/cncr.23783. Erratum in: Cancer. 2008 Nov 15;113(10):2835.

30.

Predictors of mortality of idiopathic pulmonary fibrosis.

Carbone R, Balleari E, Grosso M, Montanaro F, Bottino G, Ghio R.

Eur Rev Med Pharmacol Sci. 2008 Mar-Apr;12(2):97-104. Review.

PMID:
18575159
31.

Accuracy in suspicious lung infiltrations.

Carbone R, Balleari E, Ghio R.

Thorax. 2008 Jun;63(6):568; author reply 568. No abstract available.

PMID:
18511647
32.

A pleural effusion due to extramedullary pleural plasmacytoma: a case report.

Balleari E, Carbone RG, Grosso M, Ghio R.

Intern Emerg Med. 2008 Sep;3(3):289-91. doi: 10.1007/s11739-008-0119-1. Epub 2008 Feb 12. No abstract available.

PMID:
18265936
33.

Soluble molecules and bone metabolism in multiple myeloma: a review.

Zoppoli G, Balleari E, Ghio R.

Clin Cases Miner Bone Metab. 2008 Jan;5(1):67-70.

34.

The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways.

de Totero D, Meazza R, Capaia M, Fabbi M, Azzarone B, Balleari E, Gobbi M, Cutrona G, Ferrarini M, Ferrini S.

Blood. 2008 Jan 15;111(2):517-24. Epub 2007 Oct 15.

35.

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.

Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M, Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M.

Br J Haematol. 2007 Jul;138(2):186-95.

PMID:
17593025
36.

Granulocytic sarcoma: an unusual cause of spinal cord compression.

Balleari E, Panarello S, Capello E, Grosso M, Passalia C, Pitto P, Raggi F, Roccatagliata L, Cabiddu F, Ghio R.

Int J Clin Oncol. 2007 Jun;12(3):234-7. Epub 2007 Jun 27. Review.

PMID:
17566850
37.

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.

Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.

Ann Hematol. 2006 Mar;85(3):174-80. Epub 2006 Jan 12.

PMID:
16408206
38.

Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.

de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, Balleari E, Pierri I, Fabbi M, Capaia M, Azzarone B, Gobbi M, Ferrarini M, Ferrini S.

Blood. 2006 May 1;107(9):3708-15. Epub 2006 Jan 3.

39.

Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience.

Villa G, Balleari E, Carletto M, Grosso M, Clavio M, Piccardo A, Rebella L, Tommasi L, Morbelli S, Peschiera F, Gobbi M, Ghio R.

J Exp Clin Cancer Res. 2005 Sep;24(3):355-61.

PMID:
16270521
40.

Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.

Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A.

Leuk Res. 2006 Mar;30(3):283-5. Epub 2005 Aug 18.

41.

Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?

Clavio M, Balleari E, Garrone A, Ballerini F, Varaldo R, Michelis GL, Balocco M, Abdall N, Colombo N, Grasso R, Gobbi M.

J Exp Clin Cancer Res. 2005 Mar;24(1):5-16. Review.

PMID:
15943026
42.

Medullary hyperplastic hematopoiesis in thalassemia: incidental increased Tc-99m sestamibi bone marrow uptake.

Villa G, Tommasi L, Colombo B, Balleari E.

Clin Nucl Med. 2005 Feb;30(2):135-6. No abstract available.

PMID:
15647690
43.

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.

Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM.

Br J Haematol. 2005 Jan;128(2):204-9.

PMID:
15638854
44.

Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.

Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzarà A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC.

Ann Hematol. 2005 Mar;84(3):167-76. Epub 2004 Nov 30.

PMID:
15592833
45.

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.

Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.

Ann Hematol. 2004 Nov;83(11):696-703. Epub 2004 Aug 18.

PMID:
15322763
46.

Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases.

Balleari E, Ghio R, Falcone A, Musto P.

Leuk Lymphoma. 2004 Apr;45(4):735-8.

PMID:
15160948
47.

Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression.

de Totero D, Montera M, Rosso O, Clavio M, Balleari E, Foa R, Gobbi M.

Hematol J. 2004;5(2):152-60.

PMID:
15048066
48.

Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.

Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, Rosati P, Venturino C, Varaldo R, Gobbi M, Ghio R, Rodriguez G.

Eur J Haematol. 2004 Feb;72(2):113-20.

PMID:
14962248
49.

Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.

Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.

J Exp Clin Cancer Res. 2002 Dec;21(4):481-7.

PMID:
12636093

Supplemental Content

Loading ...
Support Center